Diagnostic value of 16 cellular tumor markers for metastatic thyroid cancer: An immunohistochemical study

Anticancer Research

Volumn 31, Issue 10, 2011, Pages 3433-3440

  Liang, Huasheng ^a   Zhong, Yuhua ^a   Luo, Zuojie ^a   Huang, Yu ^b   Lin, Huade ^c   Zhan, Song ^a   Xie, Kaiqing ^d   Li, Qingdi Quentin ^e  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b Guangxi Provincial Corps Hospital   (China)

^c Department of Hepatobiliary and Endocrine Surgery   (China)

^d SOUTHERN MEDICAL UNIVERSITY   (China)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Biomarker; Diagnosis; Immunohistochemistry; Metastasis; Sensitivity; Specificity; Thyroid cancer

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; CHEMOKINE RECEPTOR CXCR4; CYCLINE; FRAGILE HISTIDINE TRIAD PROTEIN; GELATINASE A; GELATINASE B; HECTOR BATTIFORA MESOTHELIAL 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN P16; PROTEIN P53; SECURIN; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN C;

ARTICLE; CANCER DIAGNOSIS; CANCER MORPHOLOGY; CANCER PATIENT; CANCER SURGERY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; MICROARRAY ANALYSIS; ONCOGENE C MYC; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID TUMOR; UNDIFFERENTIATED CARCINOMA; UPREGULATION;

HUMANS; IMMUNOHISTOCHEMISTRY; LOGISTIC MODELS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 80054732016     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Daa T, Kodama M, Kashima K, Yokoyama S, Nakayama I and Noguchi S: Identification of basic fibroblast growth factor in papillary carcinoma of the thyroid. Acta Pathol Jpn 43: 582-589, 1993. (Pubitemid 23303516)
2. Yasuoka H, Kodama R, Hirokawa M, Takamura Y, Miyauchi A, Sanke T and Nakamura Y: CXCR4 expression in papillary thyroid carcinoma: induction by nitric oxide and correlation with lymph node metastasis. BMC Cancer 8: 274-280, 2008.
3. Wagner PL, Moo TA, Arora N, Liu YF, Zarnegar R, Scognamiglio T and Fahey TJ: The chemokine receptors CXCR4 and CCR7 are associated with tumor size and pathologic indicators of tumor aggressiveness in papillary thyroid carcinoma. Ann Surg Oncol 15: 2833-2841, 2008.
4. Maeta H, Ohgi S and Terada T: Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas. Virchows Arch 438: 121-128, 2001. (Pubitemid 32186579)
5. Friguglietti CU, Mello ES, Castro IV, Filho GB and Alves VA: Metalloproteinase-9 immunoexpression and angiogenesis in thyroid follicular neoplasms: relation to clinical and histopathologic features. Head Neck 22: 373-379, 2000. (Pubitemid 30413303)
6. Maruyama S, Kawata R and Shimada T: Study of matrix metalloproteinase-2 and -9 in thyroid papillary cancer. Nippon Jibiinkoka Gakkai Kaiho 103: 499-505, 2000.
7. Batistatou A, Charalabopoulos K, Nakanishi Y, Vagianos C, Hirohashi S, Agnantis NJ and Scopa CD: Differential expression of dysadherin in papillary thyroid carcinoma and microcarcinoma: correlation with E-cadherin. Endocr Pathol 19: 197-202, 2008.
8. Coppee F, Depoortere F, Bartek J, Ledent C, Parmentier M and Dumont JE: Differential patterns of cell cycle regulatory proteins expression in transgenic models of thyroid tumours. Oncogene 17: 631-641, 1998. (Pubitemid 28401032)
9. Laco J and Ryska A: The use of immunohistochemistry in the differential diagnosis of thyroid gland tumors with follicular growth pattern. Cesk Patol 42: 120-124, 2006.
10. Boelaert K, McCabe CJ, Tannahill LA, Gittoes NJ, Holder RL, Watkinson JC, Bradwell AR, Sheppard MC and Franklyn JA: Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. J Clin Endocrinol Metab 88: 2341-2347, 2003. (Pubitemid 36549916)
11. Liang QC, Wei QY and Fan SQ: Expression of VEGF-C and angiogenesis, and lymphangiogenesis in papillary thyroid carcinoma. Zhong Nan Da Xue Xue Bao Yi Xue Ban 31: 414-416, 2006.
12. Siironen P, Ristimäki A, Narko K, Nordling S, Louhimo J, Andersson S, Haapiainen R and Haglund C: VEGF-C and COX-2 expression in papillary thyroid cancer. Endocr Relat Cancer 13: 465-473, 2006. (Pubitemid 43886669)
13. Franchi A, Massi D, Palomba A, Biancalani M and Santucci M: CDX-2, cytokeratin 7 and cytokeratin 20 immunohistochemical expression in the differential diagnosis of primary adenocarcinomas of the sinonasal tract. Virchows Arch 445: 63-67, 2004. (Pubitemid 39044270)
14. Ordonez NG: The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Hum Pathol 35: 697-710, 2004.
15. Bunone G, Vigneri P, Mariani L, Butó S, Collini P, Pilotti S, Pierotti MA and Bongarzone I: Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 155: 1967-1976, 1999.
16. Yu XM, Lo CY, Chan WF, Lam KY, Leung P and Luk JM: Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clin Cancer Res 11: 8063-8069, 2005. (Pubitemid 41698749)
17. Kato N, Tsuchiya T, Tamura G and Motoyama T: E-cadherin expression in follicular carcinoma of the thyroid. Pathol Int 52: 13-18, 2002. (Pubitemid 34299208)
18. Brecelj E, Frkovic Grazio S, Auersperg M and Bracko M: Prognostic value of E-cadherin expression in thyroid follicular carcinoma. Eur J Surg Oncol 31: 544-548, 2005. (Pubitemid 40724097)
19. Mitselou A, Ioachim E, Peschos D, Charalabopoulos K, Michael M, Agnantis NJ and Vougiouklakis T: E-cadherin adhesion molecule and syndecan-1 expression in various thyroid pathologies. Exp Oncol 29: 54-60, 2007. (Pubitemid 46713481)
20. Tan H, Ye K and Wang Z: Clinicopathologic evaluation of immunohistochemical CD147 and MMP-2 expression in differentiated thyroid carcinoma. Jpn J Clin Oncol 38: 528-533, 2008.
21. Cavalheiro BG, Junqueira CR and Brandao LG: Expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinase 2 (TIMP-2) in medullary thyroid carcinoma: prognostic implications. Thyroid 18: 865-871, 2008.
22. Tallini G, Garcia-Rostan G, Herrero A, Zelterman D, Viale G, Bosari S and Carcangiu ML: Downregulation of p27kip1 and CXCR4/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. Am J Surg Pathol 23: 678-685, 1999. (Pubitemid 29262831)
23. Hwang JH, Hwang JH, Chung HK, Kim DW, Hwang ES, Suh JM, Kim H, You KH, Kwon OY, Ro HK, Jo DY and Shong M: CXC chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells. J Clin Endocrinol Metab 88: 408-416, 2003. (Pubitemid 36115196)
24. De Falco V, Guarino V, Avilla E, Castellone MD, Salerno P, Salvatore G, Faviana P, Basolo F, Santoro M and Melillo RM: Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer. Cancer Res 67: 11821-11829, 2007.